8-K/A: Iradimed Reports Q2 2026 Results, Reaffirms Guidance

Iradimed Corporation announced its second quarter 2026 financial results, reporting $20.5 million in revenue and reaffirming its full-year 2026 guidance.

Summary

• Iradimed Corporation reported second quarter 2026 revenue of $20.5 million, a 0.5% increase from $20.4 million in the same period of 2025.
• GAAP diluted EPS for Q2 2026 was $0.41, down from $0.45 in Q2 2025.
• Non-GAAP diluted EPS for Q2 2026 was $0.46, down from $0.49 in Q2 2025.
• For the six months ended June 30, 2026, revenue increased by 6% to $42.4 million from $39.9 million in the prior year period.
• GAAP diluted EPS for the six months increased to $0.86 from $0.82 in the prior year period.
• Non-GAAP diluted EPS for the six months increased to $0.95 from $0.91 in the prior year period.
• The company declared a regular quarterly cash dividend of $0.20 per share, payable on August 28, 2026.
• Full-year 2026 revenue guidance is reaffirmed at $91.0 million to $96.0 million, with GAAP diluted EPS of $1.90 to $2.05.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, with modest revenue growth and reaffirmation of full-year guidance, but a decrease in net income and EPS for the quarter.

Positives

• Revenue for the six months ended June 30, 2026, increased by 6% to $42.4 million compared to $39.9 million in the same period of 2025.
• GAAP diluted EPS for the six months ended June 30, 2026, increased by 5% to $0.86 per diluted share from $0.82 in the prior year period.
• Non-GAAP diluted EPS for the six months ended June 30, 2026, increased by 4% to $0.95 per diluted share from $0.91 in the prior year period.
• Domestic monitor unit bookings set a record in the second quarter.
• Bookings for the new 3870 IV pump aligned with expectations, with over 70% of new pump orders for the quad stack configuration.
• Full-year 2026 revenue guidance of $91.0 million to $96.0 million was reaffirmed.
• A regular quarterly cash dividend of $0.20 per share was declared.
• Cash flow from operations for the six months ended June 30, 2026, increased by 18% to $14.2 million.

Negatives

• Revenue for the three months ended June 30, 2026, increased by only 0.5% to $20.5 million compared to $20.4 million in the same period of 2025.
• Net income for the three months ended June 30, 2026, decreased by 10% to $5.2 million compared to $5.8 million in the same period of 2025.
• GAAP diluted EPS for the three months ended June 30, 2026, decreased by 9% to $0.41 per diluted share from $0.45 in the same period of 2025.
• Non-GAAP diluted EPS for the three months ended June 30, 2026, decreased by 7% to $0.46 per diluted share from $0.49 in the same period of 2025.
• Gross profit margin for the three months ended June 30, 2026, was 74%, down from 78% in the comparable period of 2025.
• Cash flow from operations for the three months ended June 30, 2026, decreased by 23% to $5.9 million compared to $7.7 million in the same period of 2025.

Risks

• Potential for unanticipated costs or delays associated with regulatory matters, including FDA actions or requests.
• Failure to obtain or maintain regulatory approvals or clearances.
• Reliance on a limited number of products.
• Ability to retain key personnel and hire additional qualified professionals.
• Potential for adverse application of environmental, health, and safety laws.
• Market acceptance of new products.
• Potential for product recalls, patient adverse events, or deaths.
• Challenges in enforcing intellectual property rights and defending against infringement claims.

Future Outlook

The company expects third quarter 2026 revenue of $23.0 million to $24.5 million, with GAAP diluted EPS of $0.49 to $0.54 and non-GAAP diluted EPS of $0.54 to $0.59. Full-year 2026 guidance is reaffirmed at $91.0 million to $96.0 million in revenue, with GAAP diluted EPS of $1.90 to $2.05 and non-GAAP diluted EPS of $2.09 to $2.24. The company anticipates higher gross margins in the second half of the year due to expected efficiencies from increased volume and experience with the new 3870 pump.

Management Comments

• "The second quarter marked the first step in the actual launch of the new 3870 MR IV pump and transitioning of IV pump revenue from the older 3860 to this next-generation 3870 platform."
• "Second-quarter revenue was in line with our expectations, and the initial 3870 shipments met our plan."
• "We anticipate that as experience and volumes build through the balance of the year, we will continue to gain efficiencies, which we expect will be reflected in a higher gross margin in the second half of the year."
• "We have been very pleased with our bookings for the quarter as domestic monitor unit bookings set a record, and the new 3870 bookings aligned with our expectations as we continue to get the 3870 in front of more customers."
• "Of note, more than 70% of new pump orders were for our quad stack configuration of four pumps on a single IV pole, an indication that customers are standardizing on this configuration for the 3870, and doubling the number of pump channels from the previous norm."
• "We continue to expect the 3870 revenues to ramp significantly through the second half of the year."

Industry Context

StockSavvy.ai notes that Iradimed operates in the specialized niche of MRI-compatible medical devices. The company's focus on non-magnetic IV infusion pumps and vital signs monitors addresses a critical need for patient safety and uninterrupted care during MRI procedures. The reported results, particularly the modest revenue growth and the launch of the new 3870 pump, are being closely watched as indicators of the company's ability to execute its product roadmap and capture market share in this specialized segment.

Comparison to Industry Standards

• Specific comparable companies or industry benchmarks were not provided in the filing for direct comparison of Q2 2026 financial performance.
• The filing does not offer direct comparisons to global benchmarks for MRI-compatible medical device manufacturers.

Stakeholder Impact

• Shareholders: The reaffirmation of full-year guidance and declaration of a quarterly dividend are positive signals. However, the sequential decline in quarterly EPS and net income may temper enthusiasm.
• Customers: The company continues to focus on providing specialized MRI-compatible devices, aiming to improve patient safety and care during MRI procedures.
• Employees: The company's growth and product development efforts may lead to continued employment opportunities, though specific impacts are not detailed.

Next Steps

• Continue to gain efficiencies and improve gross margins in the second half of 2026 as experience and volumes build with the 3870 pump.
• Ramp up 3870 revenues significantly through the second half of the year.
• Continue to introduce the 3870 pump to more customers.
• Monitor and manage operational issues related to meeting demand for products.
• Execute on commercialization plans for new products.

Key Dates

Recommendation

The company is showing modest growth and has reaffirmed its full-year guidance, which is positive. However, the sequential decline in quarterly earnings and margins, coupled with the slow revenue growth in Q2, suggests a cautious approach. The successful ramp-up of the new 3870 pump in the second half of the year is critical for future performance. Therefore, a 'hold' recommendation is appropriate pending further evidence of sustained growth and margin improvement.

Keywords

MRI compatible devices, IV infusion pump, patient vital signs monitoring, medical devices, revenue guidance, earnings per share, cash dividend, financial results